Bayer AG NA Stock Timeline

2026 Feb–Mar — Proposed nationwide Roundup class settlement; elevated provisions and financial impact

Monsanto (Bayer) announced a proposed U.S. nationwide class settlement to resolve eligible current and future Roundup™ (glyphosate) claims and reached separate agreements settling other Roundup and PCB claims. Bayer said it would increase litigation provisions and liabilities materially to reflect the deals. The settlement funding was reported up to $7.25 billion with payments spread over up to 21 years and subject to court approval. [16][28]

Market perception shifted toward greater legal certainty but with recognition that settlement payments and larger provisions would meaningfully weigh on near-term earnings and cash flow. Management framed the agreements as providing "greater financial certainty" while investors balanced relief from open-ended litigation risk against the headline cost and its effect on balance sheet and cash generation. [16][4]

Bayer increased overall litigation provisions and liabilities from about €7.8 billion to roughly €11.8 billion and reported provisions for glyphosate litigation of US$11.3 billion (€9.6 billion) as of Dec 31, 2025 in its financial statements. The company said settlement funding could total up to $7.25 billion subject to court approval. [20][10][16]

2026 Mar — FY‑2025 results; guidance delivery and dividend policy continuation

Bayer published full‑year 2025 results and an outlook for 2026, reporting sales, EBITDA before special items and core EPS. Management proposed a dividend of €0.11 per share and reiterated guidance range for 2026 with stable sales and earnings on a currency-adjusted basis, though free cash flow would be heavily impacted by settlement payments. [1][2]

Investors saw evidence that operating performance had stabilised even as litigation charges and settlement cash flows dominated headline net income and free cash flow. The narrative moved toward "operational improvement under new management, but balance‑sheet and cash‑flow constraints from legacy litigation remain." [1][4]

Group sales reached €45.575 billion (currency and portfolio adjusted, +1.1% versus prior year), EBITDA before special items €9.669 billion (−4.5% year-over-year), core earnings per share €4.91 (−2.8% year-over-year), free cash flow €2.084 billion, and net financial debt €29.843 billion. [1][7]

2025 Jul–Nov — Upgraded 2025 operating guidance; extra provisions for U.S. litigation

In mid‑2025 Bayer upgraded its currency‑adjusted sales and earnings guidance for 2025 with higher ranges for sales and EBITDA before special items while also establishing additional provisions for litigation in the United States. Later in 2025 Bayer continued to face large jury verdicts and appeals in Roundup litigation. [15][29]

The juxtaposition of upgraded operating guidance and rising litigation provisions produced a conflicted investor view. Operational momentum in Crop Science and Pharmaceuticals was encouraging, but headline legal risk still made the stock feel like a turnaround story tempered by litigation overhang. [15][29]

Revised 2025 guidance on a currency‑adjusted basis set Group sales at €46–48 billion and EBITDA before special items at €9.7–10.2 billion, with core EPS guidance revised to €4.80–5.30. [15]

2024 Jan — U.S. jury awards large damages in Roundup case; share reaction

A U.S. jury ordered Bayer to pay US$2.25 billion in damages in a Philadelphia trial linked to alleged Roundup (glyphosate) cancer risks—the largest single jury award in its litigation series at that time. [25]

Each high‑value jury verdict renewed investor fears that Bayer's attempt to definitively resolve Roundup claims had failed, reviving concerns over unpredictable legal outcomes and reinforcing the perception that litigation dominated fundamentals. Short‑term sentiment turned negative with increased stock volatility. [25]

Shares fell as much as approximately 5.7% on the day of the verdict; the award represented one of the largest individual liability outcomes confronting the company's litigation program. [25]

2023 Jun–Nov — CEO transition: Bill Anderson appointed CEO; management reset

Bill Anderson became Bayer's CEO effective June 1, 2023, replacing long‑time CEO Werner Baumann who had come under pressure after the Monsanto takeover and ensuing litigation. Anderson signalled a period of "listening" and left strategic options including possible structural changes open. The Supervisory Board later extended Anderson's contract amid reported early signs of progress. [21][27]

Investors viewed the leadership change as an attempt to reset strategy and restore trust after the costly Monsanto acquisition and protracted glyphosate litigation. Early market perception leaned toward cautious optimism that an external CEO could improve capital allocation and operational focus—shifting the story from pure litigation crisis management toward possible long‑term turnaround. [21][18]

2022 — Continued litigation pressure; Supreme Court interaction and provisions

Bayer continued to face thousands of Roundup claims in the U.S. with key legal milestones including unsuccessful early efforts to limit future claims and ongoing appeals that kept material uncertainty on the balance sheet. The company made additional provisions over time to address potential liabilities. [29][19]

The market treated Bayer as a company with solid underlying industrial and pharma franchises but with an existential legal overhang. Investor framing remained "operational quality obscured by litigation risk," limiting valuation expansion despite steady revenue streams. [29]

2021 Jul — End of U.S. consumer glyphosate sales; extra provisions added earlier in 2021

Bayer announced it would stop selling glyphosate‑based herbicides for residential consumer use in the U.S. beginning in 2023 as a litigation‑risk mitigation move and earlier in 2021 took incremental litigation provisions including a €4.5 billion increase in mid‑2021. [30][29]

Management's decision to curtail consumer sales and to increase provisions underlined that Bayer regarded litigation management as a material strategic priority—reinforcing investor views that legacy litigation from the Monsanto acquisition remained the dominant near‑term risk and a constraint on shareholder returns. The company's operational businesses were still viewed as valuable but impaired by legal uncertainty. [30][29]